• This article examines whether Zimmer Biomet Holdings, trading at around US$87.64, appears to be a bargain or a value trap by exploring what the current price may be implying about the stock.
• The share price has declined 1.6% over the past week, 11.9% over the past month, and 20.0% over the last year, which can influence how the market views both its risk and potential.
• Recent coverage has focused on how Zimmer Biomet fits within the broader medical equipment space and how investors are reacting to longer term return figures, including a 29.2% decline over 3 years and a 41.3% decline over 5 years. This context helps frame whether the current market view aligns with the company’s fundamentals or has moved too far in either direction.
• Zimmer Biomet scores 5 out of 6 on Simply Wall St’s valuation checks, giving it a valuation score of 5. The rest of this article explains the different valuation approaches behind that score and then considers what the current price could mean for long term investors.

Find out why Zimmer Biomet Holdings's -20.0% return over the last year is lagging behind its peers.

Approach 1: Zimmer Biomet Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and then discounting those amounts back to today’s dollars. It is essentially asking what those future cash flows are worth right now.

For Zimmer Biomet Holdings, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $1.03b. Analyst estimates and subsequent extrapolations by Simply Wall St extend these cash flows out over the next decade, with projected free cash flow of $2.42b in 2035 according to the 10 year schedule provided.

When all those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $166.22 per share. Compared with the recent share price of roughly $87.64, the DCF output suggests the stock may be 47.3% undervalued based on these assumptions and inputs.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Zimmer Biomet Holdings is undervalued by 47.3%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Zimmer Biomet Holdings.

Approach 2: Zimmer Biomet Holdings Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it connects what you pay per share to the earnings that each share produces. It helps you judge how much investors are currently willing to pay for US$1 of earnings.

What counts as a “normal” P/E depends a lot on growth expectations and risk. Higher expected earnings growth and lower perceived risk can justify a higher P/E, while slower growth and higher risk usually point to a lower, more cautious multiple.

Zimmer Biomet currently trades on a P/E of 24.32x. That sits below the Medical Equipment industry average P/E of about 27.50x and well below the peer average of 49.42x. Simply Wall St’s Fair Ratio for Zimmer Biomet is 31.08x, which is its proprietary estimate of what a reasonable P/E might be given the company’s earnings growth profile, margins, industry, market cap and specific risks.

This Fair Ratio can be more informative than a simple industry or peer comparison because it adjusts for company specific factors rather than treating all peers as identical. Since Zimmer Biomet’s current P/E of 24.32x is below the Fair Ratio of 31.08x, the multiple based view points to the shares looking undervalued on these inputs.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Zimmer Biomet Holdings Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and that is Narratives. This is where you spell out your story for Zimmer Biomet Holdings, link it to a simple forecast for revenue, earnings and margins, and let the Simply Wall St Community page turn that into a fair value that can be compared with the current price. It will update automatically when new earnings or news arrive, and even show how different investors can land in very different places. For example, one investor focusing on U.S. execution, digital health and robotics might lean toward a higher fair value closer to the US$138 analyst target. Another who is more focused on pricing pressure, regulatory risk and acquisition integration might anchor nearer the US$96 target.

Do you think there's more to the story for Zimmer Biomet Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.